ELEMENT GLOBAL, INC. (ELGL) FORMING NEW INTERNAL COMMITTEES, FORM 10 TRANSPARENCY

Virginia Beach, VA- November 25, 2015- Element Global, Inc. (ELGL.PINKSHEETS) announces forming a number of structured internal committees.

The following committees are:

– Corporate Governance Committee

-Insider Trading Policy Committee

-Finance Charter Committee

-Executive Charter Committee

-Corporate Governance Principals Committee

-Compensation Committee

-Code of Ethics for Senior Executives Committee

-Code of Business Conduct Board

-Audit Committee

These committees are a professional necessity in providing seamless operations and independent overviews.  The US SEC requires each committee to be formed and seated prior to any FORM 10 application transmission through the US SEC EDGAR FILING system.

Furthermore, these numerous committees gives further transparency depth, giving ELGL a better corporate presence as it pertains to operational growth, industry recognitions and financial industry confidences.

As the Company moves closer to its FORM 10 filing, each of these committees are an integral part to become a fully reporting entity.  Committee chairs and other nominees on the aforementioned will be forthcoming in future news releases and within its FORM 10 filing.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090 and/or yes@yesinternational.com.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

ELEMENT GLOBAL, INC. (ELGL) UPDATES PENDING REGISTRATION STATEMENT WITH AUDITED FINANCIAL STATEMENTS

Virginia Beach, VA- November 24, 2015-ELEMENT GLOBAL, INC. (OTC.ELGL) delayed its financial reporting results beyond the allowable time frame, causing the Company to receive a “YIELD” sign on its symbol at the OTCMARKETS.COM trading platform.

Due to the complexities and requirements with the ongoing audited statements, the Company decided it would be best to provide its financial statements within a pending registration statement to be filed with the US SEC EDGAR FILING DIVISION.

Once filed, the Company waits on US SEC approval to become fully reporting under the 1934 Act. This pending FORM 10 will contain information about operational fundamentals, stock structure, financial instruments, managerial backgrounds and two-years of audited financial statements.

Upon receipt of the audited statements, they will be filed with OTCMARKETS.COM at that time, while the Company awaits US SEC approval on its registration statement.  These financials submitted to OTCMARKETS.COM in the near future should remove the “YIELD” and place the Company back under “CURRENT” status.

Once the Company is approved as a US SEC fully reporting entity, management will request up-lifting the Company’s stock to OTCQB, with an immediate uplift shortly after to that of OTCQX.

Its management’s intent to show the required financial strength, as well as, higher stock prices that should enable ELGL to qualify and uplift to a national exchange at a time warranted in the future.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090 and/or yes@yesinternational.com.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

NUTROGANICS, INC. (NUTT) ANNOUNCES RECORD THIRD QUARTER REVENUE OF OVER $4.2 MILLION

BETHESDA, Md.-November 24, 2015 – Nutroganics, Inc. (PINKSHEETS: NUTT) (“Nutroganics”) announces that it recorded $4.26 million in revenue for the third Quarter of 2015, a record third quarter for the Company and a year-over-year increase of 81% from revenue achieved in Q3 of 2014.

David Sackler, Nutroganics’ President & CEO, said, “We are pleased to announce strong quarterly revenue for Q3 2015. We continue to expand our capabilities and offerings to serve our existing customer base while adding new customers in Q4. The rest of the year looks bright and we expect continued growth in Q4.”

Nutroganics recently announced that it expects its 2016 revenue to be between $20 and 22 million, guidance which it re-affirms today.

Nutroganics’ full Q3 results are available at http://www.otcmarkets.com/stock/NUTT/filings.

About Nutroganics:

Nutroganics, Inc. acquires and grows revenue-generating businesses operating in the healthy lifestyle marketplace, and seeks to capitalize on synergies from manufacturing through distribution. Nutroganics owns Silverbow Honey Company, a producer and packager of honey products founded in 1945 and based in Moses Lake, Washington and NuStar Manufacturing, LLC, a Utah based packager of nutritional products and supplements.

For more information, contact David Sackler at dsackler@nutroganics.com or (240) 223-1000, and/or Rich Kaiser, Investor Relations, YES INTERNATIONAL, rich@yesinternational.com, 757-306-6090, www.nutroganics.com.

Forward-Looking Statements:

This release may contain forward-looking statements, which involve known and unknown risks, uncertainties, and other factors, which may cause Nutroganics’ actual results, performance, or achievements to be materially different from actual future results expressed or implied by the forward-looking statements. We undertake no obligation to update any forward-looking statements after the date of such statements.

GOLDLAND HOLDINGS CO. (GHDC) ANNOUNCES ALLEN SIMON AS CORPORATE ADVISOR

Toronto, Ontario- November 17, 2015- GoldLand Holdings Co. (GHDC:OTCPINKS), announces Mr. Allen Simon of New York, NY as its corporate advisor.  GHDC’s management is very excited to have such an accomplished business power join the GHDC team, assisting and guiding the GoldLand executives on completing ventures currently under consideration as well as long term future company growth.

Already, Mr. Simon proposed to GHDC’s Board of Directors specific product developments for retail application in El Salvador and throughout Central/South America. These new product lines include potential online markets in North, South and Central American market places.

Paul Parliament, CEO, President of GoldLand states, “This new alliance with Mr. Simon, with his knowledge and proven business track record will without a doubt, establish GoldLand as a quality investment.  Along with our already planned business partnerships, this places the Company on very solid ground.”

“I’m looking forward to working with the new team at GoldLand Holdings and building this into a real entity,” said, Mr. Allen Simon, Corporate Advisor.

Within the next week GHDC anticipate updating the progress and proposed completion of the Company’s financial audit for period ending December 2014 and quarterlies for 2015.

The Company recently filed a FORM 8-K regarding its auditor which can be read at:

http://www.sec.gov/Archives/edgar/data/1444839/000109181815000173/0001091818-15-000173-index.htm

For further information about this release, contact Kara Craig, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com.

About GoldLand Holdings Co:

GoldLand Holdings Co. (OTC-PINK: GHDC) is a diversified Company, (holding gold and silver mining properties in North America, and leased casino equipment in South America) with an aggressive growth strategy driven through mergers, acquisitions, and new ventures. This will result in a multi-divisional, financially viable and profitable wholly owned subsidiary model company.

GoldLand Holdings Co. cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

Predictive Technology Group, Inc. (PRED) Announces Issuance of US Patent for Endometriosis Treatment

Virginia Beach,  VA – November 17, 2015- Predictive Technology Group, Inc. (OTCPINKS: PRED), a biotechnology company focused on personalized patient care through novel gene-based companion diagnostics and therapeutics, announces that the United States Patent and Trademark Office has issued US Patent 9,149,499 covering Progesterone/Progestin/Cannabis Therapeutic and Method of Use for the treatment of endometriosis.  Predictive Therapeutics, LLC, a subsidiary of PRED, has exclusive rights to the patent.

About Endometriosis

According to the “The World Endometriosis Research Foundation,” endometriosis affects an estimated 1 in 10 women during their reproductive years (i.e., usually between the ages of 15 to 49).    Endometriosis is a condition where tissue, called endometrium, which lines the uterus is found outside the uterus inducing a chronic inflammatory reaction that may result in scar tissue. Endometriosis affects an estimated 176 million women worldwide regardless of their ethnic and social background. Many remain undiagnosed and are therefore not treated (http://endometriosisfoundation.org/Facts-about-endometriosis.pdf).
About Predictive Therapeutics

Predictive Technology Group, Inc. (“PRED”) is a life sciences holding company.  Predictive Therapeutics, LLC (“PRx”), a subsidiary of PRED, is focused on novel therapeutics leveraged by proprietary gene-based companion diagnostics that provide for the delivery of the most appropriate personalized patient care for the treatment of serious, chronic and debilitating diseases, www.predrx.com and www.predictivetechnologygroup.com.

For further information contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.